Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 USD | +0.68% | -6.94% | +99.32% |
May. 02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 390K | Sales 2025 * | 66.67K | Capitalization | 131M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | -57M | EV / Sales 2024 * | 336 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1,966 x |
P/E ratio 2024 * |
-3
x | P/E ratio 2025 * |
-2.76
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.33% |
Latest transcript on Cardiff Oncology, Inc.
1 day | -0.51% | ||
1 week | -7.26% | ||
Current month | -7.55% | ||
1 month | -13.27% | ||
3 months | -27.23% | ||
6 months | +129.69% | ||
Current year | +98.65% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 2.95 | +0.68% | 565 260 |
24-06-07 | 2.93 | -1.68% | 745,918 |
24-06-06 | 2.98 | 0.00% | 512,324 |
24-06-05 | 2.98 | -1.65% | 518,315 |
24-06-04 | 3.03 | -4.42% | 658,734 |
Delayed Quote Nasdaq, June 10, 2024 at 03:39 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.65% | 131M | |
+49.63% | 57.87B | |
+41.65% | 40.25B | |
-6.88% | 39.94B | |
-5.96% | 28.54B | |
+13.01% | 26.4B | |
-19.81% | 19.33B | |
+31.80% | 12.4B | |
+0.40% | 12.23B | |
+25.41% | 12.2B |
- Stock Market
- Equities
- CRDF Stock